An investigation into the mechanism of dissolution rate enhancement of poorly water-soluble drugs from spray chilled gelucire 50/13 microspheres

Journal of Pharmaceutical Sciences

Volumn 99, Issue 1, 2010, Pages 262-274

  Qi, Sheng ^a   Marchaud, Delphine ^b   Craig, Duncan Q M ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b GATTEFOSSÉ SAS   (France)

Author keywords

Dissolution; Hydration; Lipids; Liquid crystalline; Microspheres; Poorly water soluble drug; Solid dispersion

Indexed keywords

GELUCIRE; MICROSPHERE; PIROXICAM;

ARTICLE; BLOOD RHEOLOGY; CONTROLLED STUDY; DISSOLUTION; DRUG RELEASE; POLARIZATION MICROSCOPY; X RAY DIFFRACTION;

EID: 73949113481     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21832     Document Type: Article

References (32)

1. Montousse C, Pruvost M, Rodriguez F, Brossard C. 1999. Extrusion-spheronization manufacture of Gelucire matrix beads. Drug Dev Ind Pharm 25:75-80.
2. Mehuys E, Vervaet C, Gielen I, Van Bree H, Remon JP. 2004. In vitro and in vivo evaluation of a matrixin-cylinder system for sustained drug delivery. J Control Release 96:261-271.
3. Wu P, Tsai M, Huang Y, Chang J, Tsai Y. 2002. In vitro and in vivo evaluation of potassium chloride sustained release formulation prepared with saturated polyglycolyed glycerides matrices. Int J Pharm 243:119-124.
4. Khan N, Craig DQM. 2003. The influence of drug incorporation on the structure and release properties of solid dispersions in the lipid matrices. J Control Release 93:355-368.
5. Choy YW, Khan N, Yuen KH. 2005. Significance of lipid matrix aging on in vitro release and in vivo bioavailability. Int J Pharm 299:55-64.
6. Sutananta W, Craig DQM, Newton JM. 1994. An investigation into the effect of preparation conditions on the structure of mechanical properties of pharmaceutical glyceride bases. Int J Pharm 110:75-91.
7. Sutananta W, Craig DQM, Newton JM. 1994. The effects of ageing on the thermal behaviour and mechanical properties of pharmaceutical glycerides. Int J Pharm 111:51-62.
8. Khan N, Craig DQM. 2004. The role of blooming in determining the storage stability of lipid-based dosage forms. J Pharm Sci 93:2962-2971.
9. Shimpi SL, Chauhan B, Mahadik KR, Paradkar A. 2005. Stabilization and improved in vivo performance of amorphous Etoriccoib using Gelucire 50/13. Pharm Res 10:1727-1735.
10. Cavallari C, Albertini B, González-Rodríguez ML, Rodriguez L. 2002. Improved dissolution behaviour of steam-granulated piroxcaim. Eur J Pharm Biopharm 54:65-73.
11. Perissutti B, Rubessa F, Princivalle F. 2000. Solid dispersions of carbamazepine with Gelucire 44/14 and 50/13. STP Pharma Sci 10:479-484.
12. Joshi HN, Tejwani RW, Davidovich M, Sahasrabudhe VP, Jemal M, Bathala MS, Varia SA, Serajuddin ATM. 2004. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J Pharm 269:251-258.
13. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. 1998. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 87:164-169.
14. Humberstone AJ, Charman WN. 1997. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 25:103-128.
15. Passerini N, Albertini B, Perissutti B, Rodriguez L. 2006. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int J Pharm 318:92-102.
16. Passerini N, Perissutti B, Moneghini M, Voinovich D, Albertini B, Cavallari C, Rodriguez L. 2002. Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J Pharm Sci 91:699-707.
17. Cavallari C, Rodriguez L, Albertini B, Passerini N, Rosetti F, Fini A. 2004. Thermal and fractal analysis of diclofenac/Gelucire 50/13 microparticles obtained by ultrasound-assisted atomization. J Pharm Sci 94:1124-1134.
18. Englert R, Fontanesi G, Müller P, Ott H, Rehn L, Silva H. 1996. Piroxicam fast-dissolving dosage form in the treatment of patients with acute low back pain. Clin Ther 18:843-852.
19. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. 1999. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 181:143-515.
20. Fernández M, Margarit MV, Rodriguez IC, Crezo A. 1993. Dissolution kinetics of piroxicam in solid dispersions with polyethylene glycol 4000. Int J Pharm 98:29-35.
21. Yüksel N, Karataş A, Özkan Y, Savaşer A, Özkan SA, Baykara T. 2003. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: In vitro and in vivo evaluation. Eur J Pharm Biopharm 56:453-459.
22. Prabhu S, Ortega M, Ma C. 2005. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Int J Pharm 301:209-216.
23. Schwendeman SP, Tobio M, Joworowicz M. 1998. New strategies for the microencapsulation of tetanus vaccine. J Microencapsul 15:299-318.
24. Qi S, Deutsch D, Craig DQM. 2006. An investigation into the interaction between taste masking fatty acid microspheres and alkaline buffer using thermal and spectroscopic analysis. J Pharm Sci 95:1022-1028.
25. Sutananta W, Craig DQM, Newton JM. 1995. An evaluation of the mechanisms of drug release from glyceride bases. J Pharm Pharmacol 47:182-187.
26. Larsson K. 1989. Cubic lipid-water phases: Structures and biomembrane aspects. J Phys Chem 93:7304-7314.
27. Brubach JB, Ollivon M, Jannin V, Mahler B, Bourgaux C, Lesieur P, Roy P. 2004. Structural and thermal characterization of lipidic excipients and carriers by X-ray diffraction coupled to differential microcalorimetry. J Phys Chem B 108:17721-17729.
28. Shah JC, Sadhale Y, Chilulcuri DM. 2001. Cubic phase gels as drug delivery systems. Adv Drug Deliv Rev 47:229-250.
29. Kossena GA, Charman WN, Boyd BJ, Porter CJH. 2004. A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drug. J Control Release 99:217-229.
30. Clogston J, Craciun G, Hart DJ, Caffrey M. 2005. Controlling release from the lipidic cubic phase by selective alkylation. J Control Release 102:441-461.
31. Dennis AB, Farr SJ, Kellaway IW, Taylor G, Davidson R. 1990. In vivo evaluation of rapid release and sustained release Gelucire capsule formulations. Int J Pharm 65:85-100.
32. Remuñán C, Bretal MJ, Núñez A, Jato JLV. 1992. Accelerated stability study of sustained-release nifedipine tablets prepared with Gelucire. Int J Pharm 80:151-159.